Gudeng Precision Industrial Co (家登精密), a key supplier of extreme ultraviolet (EUV) pods to Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), yesterday said it is positive about growth for the next 18 months, as demand is expected to spike after its major customer’s 3-nanometer chip begins mass production later this year.
The consumption of EUV pods should increase rapidly in tandem with upgrades of process technologies, as more EUV layers would be used. Chipmakers use eight times more EUV pods for 3-nanometer process technology than for 7-nanometer technology, Gudeng said.
Based in New Taipei City’s Tucheng District (土城), Gudeng is the world’s largest EUV pod supplier, with a market share of 80 percent.
Photo: Grace Hung, Taipei Times
“We have clear order visibility until the second half of next year,” Gudeng chairman Bill Chiu (邱銘乾) told a media briefing. “We believe that revenue in the second half of this year will be better than in the first half. This will be a quite good year, and revenue should grow further next year.”
Gudeng said its revenue growth would not be affected by a key customer’s EUV tool adjustments, providing some relief to its production lines since the company’s capacity has been full for the past two years, it said.
Media reports last week said TSMC was shutting down several EUV machines in response to faltering customer demand.
However, a person within the supply chain said on condition of anonymity that TSMC is upgrading its EUV machines to cope with fast-growing demand for advanced chips.
Gudeng yesterday said that front-opening unified pod (FOUP) business provides a second growth source for its revenue this year and next.
As Chinese chipmakers accelerate new factory construction to reach self-sufficiency amid an intensifying trade dispute with the US, demand for Gudeng’s 12-inch FOUPs is spiking, Chiu said.
Gudeng, which commands a 40 percent share of China’s FOUP market, expects FOUP revenue to grow up to 40 percent year-on-year, Chiu said, adding that similar growth is expected next year.
The box-like FOUPs are used to ship, transport and store 12-inch wafers, which are unloaded from the FOUP within processing equipment to keep the wafers sterile. EUV pods are used to carry reticles when EUV tools are utilized to produce chips.
Gudeng reported that revenue last month grew 119 percent to NT$400 million (US$12.96 million) from NT$198 million in August last year. That brought the company’s revenue for the first eight months of the year to NT$2.81 billion, soaring 67.23 percent from NT$1.68 billion during the same period last year.
Separately, semiconductor equipment supplier Symtek Automation Asia (迅得機械) said that it is positive about revenue growth prospects for this year and next.
The company expects revenue to expand about 14 percent year-on-year to NT$5.6 billion, from about NT$4.9 billion last year. It aims to grow revenue by 15 percent annually next year.
“We have received NT$3 billion of orders for delivery next year,” company president Jordan Wang (王年清) told the same news conference yesterday.
To satisfy customer demand, the company plans to spend about NT$1.8 billion to build a new factory in Taoyuan’s Jhongli District (中壢), Wang said, adding that it is to start operations at the end of 2024.
Symtek counts TSMC, ASE Technology Holding Co (日月光投控) and Zhen Ding Technology Holding Ltd (臻鼎), the world’s biggest flexible printed circuit board maker, among its major clients.
Apple Inc might make one out of four iPhones in India by 2025, JPMorgan & Chase Co analysts said yesterday, as the tech giant moves some production away from China, amid mounting geopolitical tensions and strict COVID-19 lockdowns in the country. JPMorgan expects Apple to move about 5 percent of iPhone 14 production from late this year to India, which is the second-biggest smartphone market in the world after China. It is also estimating that about 25 percent of all Apple products, including Mac, iPad, Apple Watch and AirPods, would be manufactured outside China by 2025 from 5 percent currently. The US company
HEADING SOUTH: The US company chose Kaohsiung as its site as more customers, partners and start-ups have expanded their operations to the southern city Qualcomm Inc yesterday inaugurated a new innovation center in Kaohsiung as it steps up efforts to foster local start-ups and a 5G technology ecosystem in the city, following in the footsteps of its local partners. The US chip company’s move fits the Kaohsiung City Government’s plan to build a semiconductor supply chain within the next five years, highlighted by Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) first chip plant in the city. TSMC plans to start building the factory by the end of this year, and to start production of 28-nanometer and 7-nanometer chips there in 2024. Qualcomm said it had been
SLUMPING DEMAND: Inventory has climbed by up to 12 weeks as suppliers are under mounting pressure to offload excessive reserves, a TrendForce report said The price of DRAM chips is expected to fall at a steeper rate of 13 to 18 percent next quarter, as high inflation continues to weigh on demand for consumer electronics, causing chip inventories to soar, market researcher TrendForce Corp (集邦科技) said yesterday. The downtrend in DRAM prices could extend from a quarterly decline of 10 to 15 percent in the third quarter, the Taipei-based researcher said. “Demand for consumer electronics continued to stagnate during the third quarter, which used to be a high demand season,” TrendForce said in a statement. “During the quarter, memorychip consumption and shipments both showed quarterly
GlaxoSmithKline (GSK) in July made its consumer health products division a separate entity as it transforms into a world-leading biopharmaceutical company. By uniting science, technology and talent, the company is aiming to prevent and treat diseases with innovative vaccines, specialty pharmaceuticals and general medicines. GSK’s headquarters annually invests NT$192 billion (US$6.07 billion) in research and development, focusing on immune science and advanced technologies in human genetics. GSK’s drug and vaccine development focuses on infectious diseases, HIV, oncology and immunology. Investing in clinical trial research each year, GSK also brings drug development to Taiwan. It cooperates with 17 medical institutes and research
RSS